A recent study found that antiretroviral therapy adherence below 90% was associated with significantly lower odds of viral suppression among women living with HIV. Researchers analyzed data from ...

In the early 1980s, as a physician at the University of California Medical Center, researching and treating sexually transmitted viral diseases, I found myself at the epicenter of an emerging crisis ...

This study assessed longitudinal relationships between patient healthcare empowerment, engagement in care, and viral control in the Women's Interagency HIV Study, a prospective cohort study of U.S.

High stigma levels correlate with lower ART adherence and viral suppression in women with HIV, especially those who inject drugs. The study used data from the WIHS, focusing on stigma's impact on HIV ...

Self-reported measures of antiretroviral adherence vary greatly in recall time periods and response tasks. To determine which time frame is most accurate, we compared 3-, 7-day, and 1-month ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. Now, the injection has beaten daily drugs in individuals ...

PHOENIX--(BUSINESS WIRE)-- Magellan Rx Management, the full-service pharmacy benefits management division of Magellan Health, Inc. (NASDAQ: MGLN) has expanded Navigate Whole Health to include the AIDS ...

After four decades of hard-won progress toward curbing the HIV epidemic, the face of the disease is changing.

HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but ...